´ëÇѾÏÇÐȸ°¡ ¼±Á¤, ¼ö¿©ÇÏ´Â Á¦3ȸ '±¤µ¿ ¾ÏÇмú»ó' ¼ö»óÀÚ·Î °À±±¸ ±³¼ö(¿ï»ê´ë ÀÇ°ú´ëÇÐ ³»°ú), ±èÈ£±Ù ±³¼ö(¿¬¼¼´ë ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç), ÀÓ¼®¾Æ ±³¼ö(¼¿ï´ë ÀÇ°ú´ëÇÐ ³»°ú)°¡ ¼ö»óÇß´Ù.(»çÁø/Á·κÎÅÍ °À±±¸-±èÈ£±Ù-ÀÓ¼®¾Æ ±³¼ö)
±¤µ¿ ¾ÏÇмú»óÀº ´ëÇѾÏÇÐȸ¿Í ±¤µ¿Á¦¾àÀÌ °øµ¿ Á¦Á¤ÇßÀ¸¸ç À̹øÀÌ 3¹ø°´Ù.
´ëÇѾÏÇÐȸ´Â 20ÀÏ ¼¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼ ¿¸° Á¦40ȸ ´ëÇѾÏÇÐȸ Á¤±âÃÑȸ¿¡¼ °À±±¸ ±³¼ö, ±èÈ£±Ù ±³¼ö, ÀÓ¼®¾Æ ±³¼ö¿¡°Ô Á¦3ȸ ±¤µ¿ ¾ÏÇмú»óÀ» ¼ö¿©Çß´Ù°í ¹àÇû´Ù.
ÀÌ »óÀº ¼öÁØ ³ôÀº SCI Àú³Î ȤÀº ºÐ¾ßº° SCI ³í¹®ÀÇ ºñÀ²ÀÌ ³ôÀº ÇÐȸÁö¿¡ ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇÑ ³í¹®À» ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ, ±×¸®°í ´Ù¼öÀÇ SCI Àú³Î¿¡ ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇØ ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ µî Ź¿ùÇÑ ¿¬±¸ ¼º°ú¸¦ ³½ ÀÇÇÐÀÚ¿¡°Ô ¼±Á¤, ¼ö¿©µÈ´Ù.
½É»ç´Â ´ëÇѾÏÇÐȸ »óÀÓÀ§¿øȸ°¡ ¸Ã¾Æ ÃÖÁ¾ ¼ö»óÀÚ¸¦ °áÁ¤ÇÑ´Ù.
¼ö»óÀÚ¿¡°Ô´Â »óÀå°ú ÇÔ²² »ó±Ý 500¸¸¿øÀÌ ¼ö¿©ÇÑ´Ù.
ÃÖ°í ¿µÇâ·ÂÁö¼ö(IF, Impact Factor) SCI Àú³ÎÀÇ Àӻ󿬱¸ ³í¹® ¹ßÇ¥ ºÎ¹®¿¡¼± °À±±¸ ±³¼ö°¡ Lancet Oncol(IF 25.12)¿¡ ³í¹®(Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial)À» °ÔÀçÇß´Ù.
±âÃÊ¿¬±¸ ³í¹® ¹ßÇ¥ ºÎ¹®¿¡¼´Â ±èÈ£±Ù ±³¼ö°¡ Clin Cancer Res(IF 7.837)¿¡ ³í¹®(Protein Kinase C-delta-Mediated Recycling of Active KIT in Colon Cancer)¿¡ ¹ßÇ¥Çß´Ù.
ÀÓ¼®¾Æ ±³¼ö´Â ¸ðµÎ 6ÆíÀÇ SCI Àú³Î¿¡ ´ëÇѾÏÇÐȸÁö¸¦ Àοë, ³í¹®À» °ÔÀçÇÔÀ¸·Î½á ±¹³» ÃÖ°í ±ÇÀ§ÀÇ ¾ÏÇÐȸÁö°¡ ¸í½Ç»óºÎÇÑ ±¹Á¦Àú³Î·Î µµ¾àÇϴµ¥ Å©°Ô ±â¿©Çß´Ù.
´ëÇѾÏÇÐȸ °ü°èÀÚ´Â “ÇÐȸ ⸳ 40ÁÖ³âÀ» ±â³äÇÏ´Â ÀÚ¸®¿¡¼ ¾Ï Ä¡·áºÐ¾ßÀÇ ±âÃÊ-ÀÓ»ó ¿¬±¸¿¡ ¸¹Àº ±â¿©¸¦ ÇÑ È¸¿øµé¿¡°Ô ¶æ ±íÀº »óÀ» ¼ö¿©ÇÏ°Ô µÅ ±â»Ú´Ù”¸ç “ÇâÈÄ ½Éµµ ±íÀº ¿¬±¸°¡ ÁøÇàµÅ Çѱ¹ ÀÇÇÐÀÇ ±¹Á¦Àû À§»ó Á¤¸³¿¡ ±â¿©ÇÒ ¼ö ÀÖ±æ ±â´ëÇÑ´Ù"°í ÀüÇß´Ù.